What is Hummingbird?
Hummingbird, operating within the medical technology sector, is the developer of the Hummingbird Tympanostomy Tube System (TTS). This groundbreaking technology enables Ear, Nose, and Throat (ENT) surgeons to perform pediatric ear tube placements in an office setting, eliminating the need for general anesthesia. This innovative approach addresses the complexities and costs associated with traditional operating room procedures, offering a safer, more streamlined, and cost-effective alternative for families. The Hummingbird procedure is designed to significantly reduce overall healthcare expenses, potentially by up to 65%, while allowing children to resume their normal activities immediately post-treatment. The company specifically targets pediatric patients experiencing recurrent ear infections, aiming to enhance the treatment experience for both children and their parents.
How much funding has Hummingbird raised?
Hummingbird has raised a total of $5.4M across 3 funding rounds:
Series A
$4.4M
Debt
$976K
Debt
$83K
Series A (2014): $4.4M, investors not publicly disclosed
Debt (2015): $976K, investors not publicly disclosed
Debt (2021): $83K supported by PPP
Key Investors in Hummingbird
PPP
Public-Private Partnership
What's next for Hummingbird?
With the recent influx of substantial expansion capital, Hummingbird is poised for significant scaling and market expansion. The enterprise-level funding suggests a strategic focus on broadening its operational reach, potentially investing in further research and development to enhance its product offerings, and increasing its sales and marketing efforts. The company's ability to offer a cost-effective and less invasive solution for a common pediatric procedure positions it for strong adoption within the healthcare market. Future developments may include expanding the application of its technology to other procedures or patient demographics, further solidifying its market leadership in innovative pediatric medical devices.
See full Hummingbird company page
